The Global Companion Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
The report takes readers through the comprehensive companion diagnostics deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering companion diagnostics partnering deals.
The report presents average financial deal terms values for companion diagnostics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The middle section of the report explores the leaders in the companion diagnostics partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
One of the key highlights of the report is that over 250 online deals records of actual companion diagnostics deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
Contract documents provide a wealth of information for the reader and provide an insight into the flexibility of a potential prospective partner and their associated deal terms, many of which will ultimately affect the success of the deal. By examining actual company deals and contracts, the reader can begin to establish the answer to a number of questions, such as –
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Finally the report concludes by looking into the future of companion diagnostics partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial activities.
Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the companion diagnostics field.
By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the companion diagnostics market and will be familiar with the values and structures of the deals being signed within it.
Global Companion Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.
Global Companion Diagnostics Partnering 2010-2015 includes:
- Trends in companion diagnostics dealmaking in the biopharma industry since 2010
- Analysis of companion diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life companion diagnostics deals
- Access to companion diagnostics contract documents
- The leading companion diagnostics deals by value since 2010
- Most active companion diagnostics dealmakers since 2010
- The leading companion diagnostics partnering resources
In Global Companion Diagnostics Partnering 2010-2015, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target